Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Docetaxel chemotherapy improves symptoms and survival in men with metastatic hormone-refractory prostate cancer (HRPC). However, ∼50% of patients do not respond to Docetaxel and are exposed to significant toxicity without direct benefit. This study aimed to identify novel therapeutic targets and predictive biomarkers of Docetaxel resistance in HRPC. We used iTRAQ-mass spectrometry analysis to identify proteins associated with the development of Docetaxel resistance using Docetaxel-sensitive PC3 cells and Docetaxel-resistant PC3-Rx cells developed by Docetaxel dose escalation. Functional validation experiments were performed using recombinant protein treatment and siRNA knockdown experiments. Serum/plasma levels of the targets in patient samples were measured by ELISA. The IC50 for Docetaxel in the PC3-Rx cells was 13-fold greater than the parent PC-3 cell line (P = 0.004). Protein profiling identified MIC-1 and AGR2 as respectively up-regulated and down-regulated in Docetaxel-resistant cells. PC-3 cells treated with recombinant MIC-1 also became resistant to Docetaxel (P = 0.03). Conversely, treating PC3-Rx cells with MIC-1 siRNA restored sensitivity to Docetaxel (P = 0.02). Knockdown of AGR2 expression in PC3 cells resulted in Docetaxel resistance (P = 0.007). Furthermore, increased serum/plasma levels of MIC-1 after cycle one of chemotherapy were associated with progression of the cancer (P = 0.006) and shorter survival after treatment (P = 0.002). These results suggest that both AGR2 and MIC-1 play a role in Docetaxel resistance in HRPC. In addition, an increase in serum/plasma MIC-1 level after cycle one of Docetaxel may be an indication to abandon further treatment. Further investigation of MIC-1 as a biomarker and therapeutic target for Docetaxel resistance in HRPC is warranted. [Cancer Res 2009;69(19):7696–7703]
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“A high proportion of patients experience significant toxicity with 42% experiencing nausea, vomiting, or both, 30% any grade of sensory neuropathy and 26% z1 serious adverse event (2).”
BackgroundResultInfluentialTumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1
Johnen, H., Lin, S., Kuffner, T., Brown, D. A., Tsai, V. W.-W., Bauskin, A. R., Wu, L., Pankhurst, G., Jiang, L., Junankar, S., et al. (2007) · Nature Medicine · doi:10.1038/nm1677 · Cited by 612 · cited 2×
“This is consistent with data demonstrating that weight loss is associated with elevated MIC-1 levels (19), a factor often associated with poorer performance status.”
BackgroundResultSelf-citationMolecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent
Chang, B.-D., Swift, M. E., Shen, M., Fang, J., Broude, E. V., & Roninson, I. B. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012602599 · Cited by 312
Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer
Bauskin, A. R., Brown, D. A., Kuffner, T., Johnen, H., Luo, X. W., Hunter, M., & Breit, S. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4067 · Cited by 251 · cited 3×
“Serum MIC-1 levels have been linked to tumor burden in other studies (31, 38); however, in prostate cancer, serum levels of MIC-1 are an independent marker of higher-grade (Gleason sum 7) tumors (16, 39), not stage and lymph node spread, suggesting that these findings are not solely due to tumor burden (39).”
BackgroundSelf-citation
Cited by
Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
Prensner, J. R., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003180 · Cited by 472
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
MITF in melanoma: mechanisms behind its expression and activity
Hartman, M. L., & Czyz, M. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1791-0 · Cited by 320
Breit, S. N., Johnen, H., Cook, A. D., Tsai, V. W. W., Mohammad, M. G., Kuffner, T., Zhang, H. P., Marquis, C. P., Jiang, L., Lockwood, G., et al. (2011) · Growth Factors · doi:10.3109/08977194.2011.607137 · Cited by 247
“Indeed, serum MIC-1/GDF15 level estimation is clinically useful in a number of inflammatory and malignant diseases such as cancer of the colon, prostate, ovary, pancreatic and thyroid; acute cardiovascular events due to atherosclerosis and pulmonary embolism; the sequelae of atherosclerosis and rheumatoid arthritis (R…”
Local and Systemic Protumorigenic Effects of Cancer-Associated Fibroblast-Derived GDF15
Bruzzese, F., Hägglöf, C., Leone, A., Sjöberg, E., Roca, M. S., Kiflemariam, S., Sjöblom, T., Hammarsten, P., Egevad, L., Bergh, A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2259 · Cited by 127
Metadata
- Authors
- Zhao, L., Lee, B. Y., Brown, D. A., Molloy, M. P., Marx, G. M., Pavlakis, N., Boyer, M. J., Stockler, M. R., Kaplan, W., Breit, S. N., Sutherland, R. L., Henshall, S. M., & Horvath, L. G.
- Venue
- Cancer Research
- Published
- 2009-10-01
- Volume
- 69
- Issue
- 19
- Pages
- 7696-7703
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2158732421
- Cited by
- 104
- References
- 4
- FWCI
- 7.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. https://app.cochat.ai/papers/10.1158/0008-5472.can-08-4901
- The paper
- Zhao, L., Lee, B. Y., Brown, D. A., Molloy, M. P., Marx, G. M., Pavlakis, N., Boyer, M. J., Stockler, M. R., Kaplan, W., Breit, S. N., Sutherland, R. L., Henshall, S. M., & Horvath, L. G. (2009). Identification of Candidate Biomarkers of Therapeutic Response to Docetaxel by Proteomic Profiling. Cancer Research. https://doi.org/10.1158/0008-5472.can-08-4901
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.